News | September 24, 2025
Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
This predictive technology empowers people with diabetes to take preventive action before complications arise
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The lab will facilitate the development of herbal and natural-based solutions
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
IND application for EB-003 expected in early 2026
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Subscribe To Our Newsletter & Stay Updated
